Bin Zhao

Introduction: The biotransformation of drugs is critical in assessing safety and efficacy prior to human use. Cytochrome P450 (CYP; P450) enzymes are major enzymes involved in drug metabolism and bioactivation. In general, animal model systems are widely used to evaluate drug candidate toxicity and metabolism. Streptomyces strains have also been used for the metabolism of drugs screening prior to use in human medicine. Areas covered: Utilizing Streptomyces P450s uncovered by genomics to generate drug metabolites represents an additional practical means of new drug screening approach. Now, in the first such review since the advent of the post-genomic era, the authors provide an update on the present knowledge concerning the application of the Streptomyces species and associated P450s with their role(s) in drug metabolism. Expert opinion: Currently traditional biochemical methodology, such as chemical screening to identify substrates using purified enzymes, is still required for successful drug development. Nevertheless, the ability of the Streptomyces species, and their associated P450 enzymes, has shown promise for drug development because of their ability to mimic human drug-metabolizing P450. Furthermore, it should be pointed out that the metabolism of drug candidates with Streptomyces P450 may present a generation of novel products with totally different pharmacology with improved efficacy and pharmacokinetic profile.

Coelibactin is a putative non-ribosomally synthesized peptide with predicted zincophore activity and which has been implicated in antibiotic regulation in Streptomyces coelicolor A3(2). The coelibactin biosynthetic pathway contains a stereo- and regio-specific monooxygenation step catalyzed by a cytochrome P450 enzyme (CYP105N1). We have determined the X-ray crystal structure of CYP105N1 at 2.9 Å and analyzed it in the context of the bacterial CYP105 family as a whole. The crystal structure reveals a channel between the α-helical domain and the β-sheet domain exposing the heme pocket and the long helix I to the solvent. This wide-open conformation of CYP105N1 may be related to the bulky substrate coelibactin. The ligand-free CYP105N1 structure has enough room in the substrate access channel to allow the coelibactin to enter into the active site. Analysis of typical siderophore ligands suggests that CYP105N1 may produce derivatives of coelibactin, which would then be able to chelate the zinc divalent cation.

Cytochrome P450 158A2 (CYP158A2) has been shown to catalyze an unusual oxidative C−C coupling reaction to polymerize flaviolin and form highly conjugated pigments (three isomers of biflaviolin and one triflaviolin) in Streptomyces coelicolor A3(2) which protect the soil bacterium from deleterious effects of UV irradiation (Zhao B. et al. (2005) J. Biol. Chem. 280, 11599−11607). The present studies demonstrate that the subfamily partner CYP158A1, sharing 61% amino acid identity with CYP158A2, can also catalyze the same flaviolin dimerization reactions, but it generates just two of the three isomers of biflaviolin that CYP158A2 produces. Furthermore, the two CYP158A1 products have very different molar ratios compared with the corresponding CYP158A2 products, indicating that each enzyme maintains its own stereo- and regiospecificity. To find an explanation for these differences, three CYP158A1 structures have been solved by X-ray crystallography and have been compared with those for CYP158A2. The structures reveal surprising differences. Particularly, only one flaviolin molecule is present close to the heme iron in CYP158A1, and the second flaviolin molecule binds at the entrance of the putative substrate access channel on the protein distal surface 9 Å away. Our work describes two members of the same P450 subfamily, which produce the same products by oxidative C−C coupling yet show very different structural orientations of substrate molecules in the active site.

Cytochrome P450 158A2 (CYP158A2) can polymerize flaviolin to red-brown pigments, which may afford physical protection to the organism, possibly against the deleterious effects of UV radiation. We have found that the small molecule malonic acid enables cocrystallization of this mixed function oxidase with the azole inhibitor 4-phenylimidazole. The presence of malonate molecules affects the behavior of the binding of 4-phenylimidazole to CYP158A2 and increases inhibition potency up to 2-fold compared to 4-phenylimidazole alone. We report here the crystal structure of the 4-phenylimidazole/malonate complex of CYP158A2 at 1.5 A. Two molecules of malonate used in crystallization are found above the single inhibitor molecule in the active site. Those two molecules are linked between the BC loop and beta 1-4/beta 6-1 strands via hydrogen bond interactions to stabilize the conformational changes of the BC loop and beta strands that take place upon inhibitor binding compared to the ligand-free structure we have reported previously. 4-Phenylimidazole can launch an extensive hydrogen-bonding network in the region of the F/G helices which may stabilize the conformational changes. Our findings clearly show that two molecules of malonate assist the inhibitor 4-phenylimidazole to assume a specific location producing more inhibition in the enzyme catalytic activity.